Kornimate/medical-research-clean huggingface dataset:
tractography pilot study leipzig

Conditions: Intracranial Neoplasm

Summary: in this pilot study participants will undergo routine magnetic resonance imaging and routine neurosurgical care. by prospectively collecting data from both mri and patient records we want to investigate biomarkers derived from tractography and diffusion tensor imaging to predict rehabilitation potential.

patients will undergo mri before and after surgery with dti. with csd-tractography, fiber bundles and their volumes will be identified. by measuring fractional anisotropy (fa) within these volumes, a correlation with clinical outcome and recovery will be tested. also, fa frequency distributions will be used to describe white matter integrity and to thereby improve future tractography algorithms. fiber bundles of interest will be the arcuate fascicle (af), the corticospinal tract (cst), frontal aslant tract (fat), the inferior fronto-occipital fascicle (ifof), the inferior longitudinal fascicle (ilf) and the uncinate fascicle (uf).

Eligibility criteria:
inclusion criteria: * intracranial lesion * elective neurosurgical procedure exclusion criteria: * mri not applicable * cerebral ischemia during study period * pregnancy during study period * encephalitis during study period * spontaneous intracerebral hemorrhage during study period
study of the efficacy of an investigational drug in adult patients with non small-cell lung cancer (nsclc)

Conditions: Carcinoma, Non-Small-Cell Lung; Lung Neoplasms

Summary: the primary goal of the study is to evaluate an investigational drug's effectiveness as a treatment for non small-cell lung cancer (nsclc)


Eligibility criteria:
other specific inclusion/exclusion criteria may apply. in order to determine eligibility, further examination by the investigator is necessary. inclusion criteria: eligible patients must be at least 18 years of age with a diagnosis of nsclc that has gotten worse during or after treatment with platinum-based chemotherapy. patients must have at least one tumor that can be evaluated by the doctor during the investigational drug treatment. any side-effects from prior chemotherapy must have subsided, and blood and urine tests must show adequate bone marrow, liver, and kidney function. exclusion criteria: any of the following will exclude patients from study participation: receipt of more than 1 prior regimen of chemotherapy for nsclc (repeat of the same chemotherapy at different points in time count as 1 regimen). irradiation to 25% or more of bone marrow, prior high dose chemotherapy with bone marrow or stem cell support, current participation in other clinical trials, pregnant or breast-feeding women, known hiv-positive or aids-related illness.

Keywords: pharmacia
diagnostic and screening study of genetic disorders

Conditions: Tay-Sachs Disease; Porphyria, Erythropoietic; Leukodystrophy, Globoid Cell; Metabolism, Inborn Errors

Summary: objectives: i. determine the phenotypic heterogeneity of patients with genetic disorders including their clinical spectrum and natural history. ii. develop and evaluate novel methods for the treatment of genetic disorders including metabolic manipulation, enzyme manipulation, enzyme replacement, enzyme transplantation, and gene transfer techniques in these patients. iii. develop and evaluate methods for the prenatal diagnosis of genetic disorders using improved cytogenetic, biochemical, and nucleic acid techniques and amniotic fluid cells or chorionic villi in these patients.

protocol outline: patients are evaluated annually or biannually, depending on disease status and progression. patients undergo a complete medical history, an extensive family pedigree, and a physical examination. patients undergo general laboratory, imaging, physiologic, and clinical laboratory studies according to their disease type. patients undergo specialized laboratory studies including plasma and leukocyte enzyme assays, quantitative urinary mucopolysaccharides and oligosaccharides, urine and plasma glycolipids, plasma and urine amino acids, urine organic acids, lymphoblastoid culture, dna isolation from peripheral leukocytes, skin biopsy for fibroblast culture (if indicated), and medical photography. patients also receive consultations with various specialties including ophthalmology, ent, cardiology, pulmonary, gastroenterology/nutrition, hematology, neurology, orthopedics, rehabilitation medicine/physical therapy, and dermatology.

Eligibility criteria:
* suspected diagnosis (homozygous or heterozygous) of a genetic disorder including, but not limited to, one of the following: tay-sachs disease (adult form) congenital erythropoietic porphyria galactosemia mitochondrial myopathy globoid cell leukodystrophy (krabbe disease) methylmalonic acidemia isovaleric acidemia morquio type a glycogen storage disease type 1ab ornithine aminotransferase deficiency ceroid lipofuscinosis glutaric aciduria type 1 citrullinemia other malformation syndromes, lysosomal storage disorders, or peroxisomal disorders
postmarketing prospective study of melanoma patients treated with imlygic® to characterize risk of herpetic infection

Conditions: Melanoma; Herpetic Infection

Summary: a postmarketing cohort study of melanoma patients treated with imlygic (talimogene laherparepvec) in clinical practice to characterize the risk of herpetic infection with detection of talimogene laherparepvec dna among patients, close contacts, and health care providers; and long term safety in treated patients for up to 5 years after the first imlygic dose.


Eligibility criteria:
inclusion criteria: * patient has provided written informed consent * patient is an adult (≥ 18 years of age at the time of informed consent) with a diagnosis of melanoma * patient enrolled within 1 month of receiving the first dose of imlygic for the treatment of melanoma exclusion criteria: - patient has a prior history of being a subject in an interventional clinical trial for imlygic

Keywords: imlygic talimogene laherparepvec herpetic infection melanoma
optimal physiologic intravascular ultrasound imaging criteria after drug eluting stent implantation

Conditions: Coronary Disease

Summary: invasive imaging criteria of the coronary arteriography (cag) and intravascular ultrasound imaging (ivus), satisfying procedural optimization after drug eluting stent (des) implantation, were used in \< 10% ds by cag and 5-5.5mm2 msa by ivus. whether these criteria satisfy not only relieving visible stenosis but also relieving lesion specific ischemia or not were unclear. fractional flow reserve (ffr), an index of lesion specific ischemia, was proposed 0.9 as a physiologic criteria satisfying successful stent implantation by previous studies with bare metal stent. ffr after drug-eluting stent implantation can be an useful predictor for clinical outcome. but, direct comparative evaluation of the invasive imaging criteria defining as an indicator relieving myocardial ischemia were not reported. the aim of this study was to investigate angiographic and ivus parameters in which corresponding ffr and evaluate their optimal physiologic criteria after des implantation.


Eligibility criteria:
inclusion criteria: * clinical angina pectoris who underwent ivus and ffr during coronary angiography and after des implantation. * agree with informed consent * at least one segment of three major epicardial coronary arteries were consecutively enrolled in invasive cag. * post- stent ffr and ivus measurement performed at the immediately after whole pci procedures. exclusion criteria: * unable to get informed consent * low left ventricular ejection fraction less than 35% * chronic renal failure (cr \> 2.0mg/dl) * acute myocardial infarction related coronary artery * allergy to adenosine injection

Keywords: coronary atherosclerosis drug eluting stent intravascular ultrasound fractional flow reserve
comparison of small-gauge vitrectomy and conventional vitrectomy for proliferative diabetic retinopathy

Conditions: Proliferative Diabetic Retinopathy

Summary: surgical outcome of vitreous surgery for proliferative diabetic retinopathy (pdr) with conventional 20, 23, and 25-gauge vitrectomy were compared.

the 424 eyes of 347 patients of pdr who underwent vitreous surgery for persistent vitreous hemorrhage or progressive proliferative membrane were evaluated.

Eligibility criteria:
inclusion criteria: * the patients of proliferative diabetic retinopathy who underwent vitreous surgery and followed at least 6 months exclusion criteria: * the patients of proliferative diabetic retinopathy who underwent vitreous surgery but did not follow more than 6 months.

Keywords: proliferative diabetic retinopathy vitrectomy
a study to investigate whether pf-04457845 is effective in treating pain, is safe and tolerable in patients with osteoarthritis of the knee

Conditions: Osteoarthritis, Knee

Summary: inactivation of the faah (fatty acid amide hydrolase) enzyme has been shown to relieve pain and inflammation in animal studies. pf-04457845 has been shown to inactivate the faah enzyme in animals and healthy human volunteers. the purpose of this study is to evaluate whether pf-04457845 can inactivate the faah enzyme in patients experiencing pain due to oa and whether this results in these patients experiencing less pain.


Eligibility criteria:
inclusion criteria: * subjects must have a diagnosis of osteoarthritis (oa) of the knee confirmed by x-ray * subjects must be willing and able to stop all current pain therapy for the duration of study. (limited and specific pain therapy will be available throughout the study) * subjects can be male or female between the ages of 18 and 75 years inclusive, but female subjects must not be able become pregnant exclusion criteria: * subjects must not have any condition or medical history that might interfere with their ability to complete the study assessments

Keywords: cross-over evaluate the efficacy of pf-04457845 in relieving pain due to osteoarthritis oa knee osteoarthritis of knee pain due to osteoarthritis
local anesthetic concentration and rebound pain

Conditions: Rebound Pain

Summary: the rebound pain after nerve block could interfere with patient's recovery and rehabilitation. it is not known how local anesthetic concentrations affect rebound pain. the aim of this study is evaluation of the effect of local anesthetic concentration on rebound pain after interscalene block for shoulder surgery.

shoulder surgery is related to more than moderate pain after surgery. interscalene nerve block could reduce the postoperative pain effectively. when the effect of nerve block ends, however, rebound pain could appear. the rebound pain could interfere with patient's recovery and rehabilitation. the mechanism of rebound pain is not well known. one of possible mechanism is that the pain stimulus that was blocked suddenly comes out, and it is perceived as more severe pain. the strength of the block may vary depending on the concentration of the local anesthetic. therefore, the concentration of local anesthetics could affect rebound pain. the aim of this study is evaluation of the effect of local anesthetic concentration on rebound pain after interscalene block for shoulder surgery.

Eligibility criteria:
inclusion criteria: * elective shoulder surgery under general anesthesia and interscalene block for postoperative pain exclusion criteria: * contraindication of interscalene block: pulmonary disease, lung resection history, brachial nerve injury * diabetic neuropathy * adverse drug reaction history to ropivacaine, fentanyl * impaired coagulation
real-world evaluation of diagnostic and treatment strategies in low-risk basal cell carcinoma

Conditions: Basal Cell Carcinoma

Summary: basal cell carcinoma (bcc) is the most prevalent form of cancer among the caucasian population. there are several subtypes of bcc with different clinical characteristics and treatment strategies. superficial and nodular bccs are low-risk bcc subtypes. the diagnosis and subtype of bcc can be confirmed by means of punch biopsy, but non-invasive diagnosis by means of optical coherence tomography (oct) is proven to be a non-inferior alternative diagnostic instrument. besides, non-invasive topical treatment is recommended as valuable treatment alternative to surgical excision for low-risk bcc. since non-invasive diagnosis and treatment for low-risk bcc is being implemented into daily practice, we want to evaluate the real-world effectiveness of different invasive and non-invasive diagnostic and treatment strategies in the management of low-risk bcc. this real-world evidence will enhance our understanding of these management strategies for low-risk bcc in daily practice.


Eligibility criteria:
inclusion criteria: * patients ≥18 years old * diagnosis of low-risk bcc based on cde with oct confirmation or with histopathological verification in case oct diagnosis is doubtful. * tumors meeting the criteria for low-risk bcc * patient is able to understand the instruction regarding the study participation and application of imq treatment exclusion criteria: * tumor location in the h-zone of the face or hairy scalp, anogenital area * diagnosis of recurrent bcc or previous skin cancer within 2cm of the treatment area * strong suspicion/diagnosis of high-risk bcc subtype or other skin condition on oct or punch biopsy * women who are pregnant or breastfeeding * previous allergy or intolerance to imq * no concurrent use any other systemic chemopreventive or immunosuppressive medication during the treatment period, 30 days before start and 3 months after the end of treatment * limited understanding of the dutch language and not being able to give informed consent

Keywords: imiquimod surgical excision
hemostatic disorders on intensive care patients.

Conditions: Hemostatic Disorder

Summary: 1. to assess the incidence of hemostatic disorders among icu patients. 2. to establish a relationship between supportive treatment and survival in patients with coagulopathy in icu. 3. to provide solutions that can help in reduction of the incidence of hemostatic disorders in icu patients.

hemostasis is the physiological process that stops bleeding at the site of an injury while maintaining normal blood flow elsewhere in the circulation. blood loss is stopped by formation of a hemostatic plug. the endothelium in blood vessels maintains an anticoagulant surface that serves to maintain blood in its fluid state, but if the blood vessel is damaged components of the subendothelial matrix are exposed to the blood. several of these components activate the two main processes of hemostasis to initiate formation of a blood clot, composed primarily of platelets and fibrin. many critically ill patients develop hemostatic abnormalities, ranging from isolated thrombocytopenia to complex defects, such as dic. coagulation abnormalities are commonly found in critically ill patients. prompt and proper identification of the underlying cause of these coagulation abnormalities is required, since each coagulation disorder necessitates very different therapeutic management strategies. management of coagulopathy the key basic management principle of all coagulopathies is that the decision to transfuse blood products should not be based on the results of coagulation tests alone, rather an individualized approach is warranted. it is imperative to synthesizes all the available clinical data and treat the underlying cause. in summary, hemostatic disorders are very common in the critically ill. blood product support is frequently required, but there is only a very limited evidence-base to support its use. in many cases, no specific product support is required and the key management step is the treatment of the condition underlying the coagulopathy .

Eligibility criteria:
inclusion criteria: * intensive care unit patients,aged more than 18 years . * any acquired bleeding disorders (platelet disorders; thrombocytopenia, acquired thrombocythemia and thrombocytosis, acquired coagulation defect, thrombophilia ) diagnosed in critical care unit in assiut university in one year time frame exclusion criteria: * patient less than 18 years. * patients with inherited platelet defects ( amegakaryoctye aplasia and bernard soulir syndrome) * patients with inherited coagulation defects (e.g.hemophilia , von willebrand disease and any inherited coagulation defect.
home-based pulmonary rehabilitation for copd patients

Conditions: COPD, Chronic Obstructive Pulmonary Disease

Summary: objectives the objective of this project is to motivate patients with copd to incorporate the habit of doing daily mindful physical activity by using the proposed home-based pulmonary rehabilitation program that integrates video guided exercises, activity monitoring daily steps and health coaching. this program will allow patients to complete pulmonary rehabilitation (pr) at home and promote behavior change and lead to a more active lifestyle for patients with copd who have been prescribed pr. the program will be able to effectively monitor daily step count. a health coach will receive more this detailed data and will guide weekly health coaching sessions designed to increase awareness of the physical activities completed and ignite inner motivation for healthy behaviors. the proposed pr program is innovative and responds to an unmet need in chronic care for copd patients in the context of covid-19 pandemic and it mitigates the common accessibility barriers.

specific aims will guide the proposed project: * aim 1: to determine the feasibility of the proposed home-based pr program. we will additionally address adherence and appropriateness of the program. * aim 2: to determine improvements in quality of life and mental health of the proposed home-based pr determined. * aim 3: to evaluate if the average number of daily step counts increase after the home-based pr program

Eligibility criteria:
inclusion criteria: * men and women age 40 years and older * fev1 \<80% or less (forced expiratory volume in one second) as documented by pulmonary function. * medical diagnosis of copd, gold classification b,d, and c based on symptoms and history of exacerbations. * the patients must be able to access a smart-phone or computer tablet with internet service. exclusion criteria: * unable to perform low intensity exercise. * patients with a high likelihood of being lost to follow-up or contact (patients with active chemical dependency), are planning to move, are not living in the healthcare area. * patients with an inability to provide good data or follow commands (patients who are disoriented, have a severe neurologic or psychiatric condition).

Keywords: tele-health behavioural change motivational interviewing home-based exercise self-related health quality of life
the effect of different muscle training on activities of daily living in copd

Conditions: Quality of Life; Anxiety

Summary: chronic obstructive pulmonary disease (copd) contributes significantly to global morbidity and mortality; it is a disease that affects an estimated 210 million people worldwide and is the third most common cause of death. copd is identified by persistent airflow limitation and is associated with progressively worsening lung function, dyspnea, health-related quality of life (hrqol), and impaired exercise capacity. poor exercise capacity is a common finding of chronic obstructive pulmonary disease (copd). central cardiopulmonary factors, respiratory muscle dysfunction, gas exchange abnormalities, and skeletal muscle dysfunction all play a role in limiting exercise capacity the aim of this study is to investigate the effects of neuromuscular electrical stimulation applied to different muscle groups (quadriceps femoris and gastrocnemius muscles) on exercise performance and quality of life in patients with stable copd and compare it with standard treatment.


Eligibility criteria:
inclusion criteria: * being between 18-75 years old, * diagnosed as group b stable copd according to gold criteria by a pulmonologist, * pao2 \>55 mm hg, paco2 \<45 mmhg in room air. exclusion criteria: * exacerbation, * cor pulmonale or respiratory muscle fatigue (abdominal paradoxical breathing), * cardiac instability (with acute mi, congestive heart failure, or uncontrollable arrhythmia), * musculoskeletal disorder (conditions affecting exercise ability), * difficulty communicating.

Keywords: copd pulmonary rehabilitation neuromuscular electrical stimulation
duloxetine for menopausal depression

Conditions: Depression; Menopause; Vasomotor Symptoms

Summary: the primary objective of the study is to determine if an eight-week intervention with duloxetine significantly reduces depressive symptoms in symptomatic menopausal women. it is hypothesized that an eight-week trial with duloxetine promotes significant improvement in depression symptoms in menopausal women. the secondary aim of the study is to examine if an eight-week intervention with duloxetine significantly reduces vasomotor symptoms in symptomatic menopausal women. it is hypothesized that an eight-week trial with duloxetine promotes significant improvement in vasomotor symptoms in menopausal women.


Eligibility criteria:
inclusion criteria: * women age 40 years old or older * menopausal symptoms of at least 3 months duration, including irregular periods and/or hot flushes * minimum score of 15 on the hamilton rating scale for depression (17-item), * patients will meet criteria for a major depressive episode, verified using the mini international neuropsychiatric interview (mini). * subjects will be able to be treated on an outpatient basis, and * subjects will be able to provide written informed consent exclusion criteria: * subjects presently taking antidepressant medication, * subjects currently using hormone replacement therapy, * other axis i disorders, except generalized anxiety disorder or panic disorder, according to the mini international neuropsychiatric interview (mini) * "uncontrolled" narrow angle glaucoma * known hypersensitivity to duloxetine or any of the inactive ingredients * treatment with a monoamine oxidase inhibitor (maoi) within 14 days of randomization or potential need to use an maoi during the study or within 5 days of discontinuation of study drug. * presence of psychotic symptoms, * history of mania or hypomania, * ham-d suicide item score \> 3, * end stage renal disease or severe renal impairment * abnormal uterine bleeding (heavy or prolonged uterine bleeding, menstrual periods occurring more frequently than every 3 weeks, bleeding after sexual intercourse, spotting between periods) that has not been evaluated by a gynecologist. * subjects with serious or unstable medical illness, including alcohol or substance abuse, cardiovascular, hepatic, respiratory, endocrine, neuralgic, or hematologic disease, history of seizure disorder * subjects taking medications that may interact with duloxetine